A pilot study of safety of sulfamethoxazole, trimethoprim and guaifenesin in pediatric and adult patients with acute bronchitis

Mayer Falcon, Carlos Iberico, Frances Guerra, Isabel Reyes, Efraín Felix, Mónica Flores, Jorge de Los Ríos, Maria E Diaz, Alberto Casas, Sergio Sanchez-Gambetta, Roberto Carrasco, Mayer Falcon, Carlos Iberico, Frances Guerra, Isabel Reyes, Efraín Felix, Mónica Flores, Jorge de Los Ríos, Maria E Diaz, Alberto Casas, Sergio Sanchez-Gambetta, Roberto Carrasco

Abstract

Objective: This exploratory study assessed the safety of the combination of sulfamethoxazole, trimethoprim and guaifenesin (STG) in adult and pediatric patients with acute bronchitis according to local labelling in Peru.

Results: We enrolled 51 pediatric and 52 adult participants diagnosed with acute bronchitis and indication of STG. The mean ages were 7.6 years (SD ± 3.2 years) and 42.8 years (SD ± 16.1) and the proportion of female patients were 51% and 65%, respectively. The duration of treatment in pediatric patients was < 5 days in 2% of patients, 5 days in 13.7%, 6-7 days, in 82.4% and > 7 days in 2% while in adults patients it was < 5 days in 17%, 5 days in 69.2%; 6-7 days in 28.8% of patients. Adverse events (AEs) were registered in 9.6% and 19.2% of pediatric and adult patients, respectively. These AEs had definite relation of causality with the study drugs in 2 adults (20% of AEs) and possible causality with the study drugs in 4 pediatric (80% of AEs) and 2 adult cases (20% of AEs). Our results provide valuable data to develop trials of pharmacovigilance where different statistical parameters should be considered to calculate an adequate sample size in studies evaluating STG in pediatric or adult patients. Trial registration NCT02879981 and NCT02902640.

Keywords: Acute bronchitis; Adverse events; Guaifenesin; Safety; Sulfamethoxazole; Trimethoprim.

References

    1. Wark P. Bronchitis (acute) BMJ Clin Evid. 2015;12:1508.
    1. Wenzel RP, Fowler AA., 3rd Clinical practice, Acute bronchitis. N Engl J Med. 2006;355:2125–2130. doi: 10.1056/NEJMcp061493.
    1. Gonzales R, Sande MA. Uncomplicated acute bronchitis. Ann Intern Med. 2000;133:981–991. doi: 10.7326/0003-4819-133-12-200012190-00014.
    1. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2017;6:CD000245.
    1. Smith SM, Fahey T, Smucny J, Becker LA. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2014;3:CD000245.
    1. Murphy M, Bradley CP, Byrne S. Antibiotic prescribing in primary care, adherence to guidelines and unnecessary prescribing–an Irish perspective. MC Fam Pract. 2012;13:43. doi: 10.1186/1471-2296-13-43.
    1. McCullough AR, Pollack AJ, Plejdrup Hansen M, Glasziou PP, Looke DF, Britt HC, et al. Antibiotics for acute respiratory infections in general practice: comparison of prescribing rates with guideline recommendations. Med J Aust. 2017;207(2):65–69. doi: 10.5694/mja16.01042.
    1. Kraus EM, Pelzl S, Szecsenyi J, Laux G. Antibiotic prescribing for acute lower respiratory tract infections (LRTI)—guideline adherence in the German primary care setting: an analysis of routine data. PLoS ONE. 2017;12(3):e0174584. doi: 10.1371/journal.pone.0174584.
    1. Nguyen AT, Gentry CA, Furrh RZ. A comparison of adverse drug reactions between high- and standard-dose trimethoprim-sulfamethoxazole in the ambulatory setting. Curr Drug Saf. 2013;8:114–119. doi: 10.2174/1574886311308020004.
    1. Macfarlane J, Holmes W, Gard P, Macfarlane R, Rose D, Weston V, Leinonen M, Saikku P, Myint S. Prospective study of the incidence, aetiology and outcome of adult lower respiratory tract illness in the community. Thorax. 2001;56:109–114. doi: 10.1136/thorax.56.2.109.
    1. Zoorob R, Sidani MA, Fremont RD, Kihlberg C. Antibiotic use in acute upper respiratory tract infections. Am Fam Physician. 2012;86:817–822.
    1. Albrecht H, Vernon M, Solomon G. Patient-reported outcomes to assess the efficacy of extended-release guaifenesin for the treatment of acute respiratory tract infection symptoms. Respir Res. 2012;13:118. doi: 10.1186/1465-9921-13-118.
    1. Albrecht HH, Dicpinigaitis PV, Guenin EP. Role of guaifenesin in the management of chronic bronchitis and upper respiratory tract infections. Multidiscip Respir Med. 2017;12:31. doi: 10.1186/s40248-017-0113-4.
    1. Bianco A, Papadopoli R, Mascaro V, Pileggi C, Pavia M. Antibiotic prescriptions to adults with acute respiratory tract infections by Italian general practitioners. Infect Drug Resist. 2018;11:2199–2205. doi: 10.2147/IDR.S170349.
    1. Morgan JR, Carey KM, Barlam TF, Christiansen CL, Drainoni ML. Inappropriate antibiotic prescribing for acute bronchitis in children and impact on subsequent episodes of care and treatment. Pediatr Infect Dis J. 2019;38(3):271–274. doi: 10.1097/INF.0000000000002117.

Source: PubMed

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

3
Abonnieren